**Supplementary Table S1. Prevalence and Comparison of Generalized Anxiety Disorder Mutually Exclusive Groups By Sociodemographic Characteristics**

|  |  |  |
| --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | **Comparisons of** **Mutually Exclusive GAD Groups** |
|  | **Weighted Prevalence % SE** | **Adjusted Odds Ratio (95% CI)** |
|  | **GAD-6mo** **n = 284** | **GAD-3-5mo** **n = 179** | **GAD-3-5mo/****NOU****n = 214** | **GAD-3-5mo** **vs.****GAD-6mo**  | **GAD-3-5mo/****NOU** **vs.** **GAD-6mo** |
| **Total** | 3.03 (0.38) | 2.00 (0.23) | 2.43 (0.23) | **--** | **--** |
| **Sex** |  |  |  |  |  |
|  Male  | 1.86 (0.32) | 1.42 (0.27) | 2.01 (0.27) | 1.00 | 1.00 |
|  Female | 4.25(0.67) | 2.60 (0.45) | 2.87 (0.47) | 0.81 (0.38-1.73) | 0.63 (0.33-1.21) |
| Wald χ21 (*p*) | -- | -- | -- | 0.29 (0.5913) | 1.93 (0.1652) |
| **Age** |  |  |  |  |  |
|  13-14 years | 1.36 (0.36) | 1.29 (0.22) | 1.59 (0.24) | 1.00 | 1.00 |
|  15-16 years | 3.75 (0.62) | 2.36 (0.44) | 2.87 (0.42) | 0.74 (0.33-1.70) | 0.75 (0.35-1.61) |
|  17-18 years | 4.37 (0.56) | 2.46 (0.46) | 2.95 (0.54) | 0.63 (0.29-1.40) | 0.62 (0.28-1.36) |
| Wald χ22 (*p*) | -- | -- | -- | 0.29 (0.5913) | 1.57 (0.4552) |
| **Race/Ethnicity** |  |  |  |  |  |
|  Non-Hispanic White | 3.54 (0.50) | 1.95 (0.30) | 2.34 (0.32) | 1.00 | 1.00 |
|  Hispanic | 1.86 (0.40) | 1.81 (0.43) | 2.13 (0.35) | 1.67 (0.86-3.25) | 1.54 (0.83-2.84) |
|  Non-Hispanic Black | 2.70 (0.59) | 2.24 (0.54) | 2.75 (0.61) | 1.49 (0.63-3.53) | 1.45 (0.63-3.33) |
|  Other | 1.74 (0.30) | 2.46 (1.07) | 3.43 (1.10) | 2.78 (1.08-7.18) | 3.21 (1.52-6.77) |
| Wald χ23 (*p*) |  |  |  | 8.17 (0.0427) | 10.90 (0.0123) |
| **Poverty Index Ratio** |  |  |  |  |  |
| > 6 | 2.73 (0.42) | 2.24 (0.45) | 2.69 (0.46) | 1.00 | 1.00 |
| ≤ 6 | 3.68 (0.56) | 2.21 (0.36) | 2.50 (0.42) | 0.72 (0.37-1.43) | 0.70 (0.36-1.38) |
| ≤ 3 | 3.15 (0.82) | 1.45 (0.28) | 1.84 (0.36) | 0.48 (0.22-1.03) | 0.49 (0.24-1.00) |
| ≤ 1.5 | 2.14 (0.50) | 1.67 (0.48) | 2.42 (0.55) | 0.83 (0.31-2.27) | 1.06 (0.41-2.72) |
| Wald χ23 (*p*) |  |  |  | 3.65 (0.3013) | 4.28 (0.2325) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration

was **≥**3 months and **<** 6 months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability

criterion was not applied; CI = confidence interval; adjusted odds ratios and 95% confidence intervals include all sociodemographic predictors.

**Supplementary Table S2. Associated Symptoms and Course Characteristics Across Generalized Anxiety Disorder Mutually Exclusive Groups**

|  |  |  |
| --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | **Comparisons of** **Mutually Exclusive GAD Groups** |
|  | **Weighted Proportion % SE** | **Adjusted Odds Ratio (95% CI)** |
| **Associated Symptoms** | **GAD-6mo** **n = 284** | **GAD-3-5mo** **n = 179** | **GAD-3-5mo/****NOU****n = 214** | **GAD-3-5mo****vs.****GAD-6mo**  | **GAD-3-5mo/****NOU** **vs.** **GAD-6mo** |
|  Restlessness, % (SE) | 71.30 (4.42) | 85.16 (3.06) | 79.75 (3.64) | 3.00 (1.54-5.85) | 1.98 (0.99-4.00) |
| Wald χ21 (*p*) |  |  |  | 10.33 (0.0013) | 3.68 (0.0551) |
|  Easily Fatigued, % (SE) | 55.78 (3.46) | 60.65 (5.86) | 60.48 (6.14) | 1.25 (0.67-2.31) | 1.30 (0.70-2.42) |
| Wald χ21 (*p*) |  |  |  | 0.49 (0.4846) | 0.68 (0.4097) |
|  Poor Concentration, % (SE) | 83.41 (3.05) | 84.60 (4.03) | 84.48 (3.44) | 1.10 (0.46-2.63) | 1.06 (0.48-2.35) |
| Wald χ21 (*p*) |  |  |  | 0.04 (0.8355) | 0.02 (0.8939) |
|  Irritable, % (SE) | 71.51(4.16) | 74.94 (4.17) | 69.04 (4.20) | 1.37 (0.66-2.83) | 1.07 (0.54-2.12) |
| Wald χ21 (*p*) |  |  |  | 0.71 (0.3998) | 0.04 (0.8467) |
|  Muscle Tension, % (SE) | 46.74 (3.47) | 46.25 (4.21) | 41.67 (3.59) | 1.07 (0.60-1.93) | 0.94 (0.55-1.60) |
| Wald χ21 (*p*) |  |  |  | 0.05 (0.8166) | 0.05 (0.8162) |
|  Sleep Disturbance, % (SE) | 70.05 (3.04) | 62.56 (2.68) | 66.06 (3.62) | 1.02 (0.65-1.60) | 0.86 (0.54-1.35) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9405) | 0.46 (0.4972) |
|  Either Restless or Muscle Tension, % (SE) | 77.83 (3.47) | 89.80 (1.96) | 85.86 (2.89) | 2.92 (1.59-5.37) | 2.02 (1.06-3.85) |
| Wald χ21 (*p*) |  |  |  | 11.85 (0.0006) | 4.52 (0.0336) |
|  One Symptom, % (SE) | 6.93 (2.61) | 2.72 (1.15) | 2.71 (1.13) | 0.32 (0.08-1.20) | 0.35 (0.11-1.08) |
| Wald χ21 (*p*) |  |  |  | 2.85 (0.0911) | 3.36 (0.0666) |
|  Two Symptoms, % (SE) | 12.34 (2.36) | 14.07 (3.51) | 20.54 (3.96) | 1.13 (0.50-2.54) | 1.74 (0.83-3.65) |
| Wald χ21 (*p*) |  |  |  | 0.09 (0.7655) | 2.18 (0.1398) |
|  Three Symptoms, % (SE) | 13.74 (3.06) | 14.63 (3.82) | 13.59 (3.55) | 0.97 (0.43-2.16) | 0.82 (0.34-1.95) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9303) | 0.21 (0.6482) |
|  Four Symptoms, % (SE) | 28.76 (4.81) | 20.06 (3.16) | 19.32 (3.16) | 0.58 (0.31-1.08) | 0.54 (0.30-1.00) |
| Wald χ21 (*p*) |  |  |  | 2.96 (0.0854) | 3.84 (0.0500) |
|  Five Symptoms, % (SE) | 17.39 (2.65) | 23.82 (3.61) | 22.04 (4.12) | 1.67 (0.86-3.25) | 1.58 (0.77-3.23) |
| Wald χ21 (*p*) |  |  |  | 2.25 (0.1340) | 1.58 (0.2092) |
|  Six Symptoms, % (SE) | 19.65 (3.08) | 24.45 (4.62) | 21.41 (4.11) | 1.44 (0.69-3.03) | 1.30 (0.63-2.68) |
| Wald χ21 (*p*) |  |  |  | 0.95 (0.3308) | 0.51 (0.4757) |
|  Number of Symptoms, *M* (SE) | 3.97 (0.14) | 4.22 (0.18) | 4.02 (0.17) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.18 (0.6730) | 0.07 (0.7947) |
| **Course Characteristics** |  |  |  |  |  |
|  Age At Onset (years), *Md* (SE) | 11.83 (0.35) | 12.14 (0.28) | 12.25 (0.30) | --- | --- |
| Wald χ21 (*p*) |  |  |  | 1253.77(<0.0001) | 4282.37(<0.0001) |
|  12-month/LT ratio, % SE | 53.92 (4.08) | 52.50 (5.16) | 49.33 (4.64) | 0.97 (0.62-1.52) | 0.90 (0.59-1.38) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9086) | 0.25 (0.6180) |
|  Number of Past Year Episodes, *M* (SE) | 2.13 (0.17) | 2.31 (0.17) | 2.45 (0.22) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.22 (0.6403) | 9.52 (0.0038) |
|  Number of Lifetime Episodes, *M* (SE) | 6.86 (0.73) | 4.90 (0.66) | 7.43 (2.38) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.03 (0.8591) | 39.39 (<0.0001) |
|  Longest Lifetime Episode (months), *M* (SE) | 43.37 (6.31) | 3.45 (0.06) | 3.47 (0.05) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 38.65 (<0.0001) | 43.69 (<0.0001) |
| Time in Episode Since Onset (months), % SE | 65.72 (4.25) | 20.99 (1.80) | 22.39 (2.72) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 22929.40 (<0.0001) | 21349.80 (<0.0001) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration was **≥**3 months and **<** 6

months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability criterion was not applied; adjusted odds ratios and 95% confidence intervals control for all significant sociodemographic predictors of GAD (sex, age, race).

**Supplementary Table S3. Associated Symptoms and Course Characteristics of Generalized Anxiety Disorder Among Threshold and Subthreshold Cases By Age Group**

|  |  |
| --- | --- |
|  | **GAD Definition** |
|  | **GAD-6mo** **n = 284** |  | **GAD-3mo** **n = 463** |  | **GAD-3mo/NOU****n = 545** |  |
| **Age Group** | **13-14** | **15-16** | **17-18** | ***Wald******χ2/F(2)******p-value*** | **13-14** | **15-16** | **17-18** | ***Wald*** ***χ2/F(2)******p-value*** | **13-14** | **15-16** | **17-18** | ***Wald******χ2/F(2)******p-value*** |
| **Associated Symptoms** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Restlessness, % SE | 55.345.66 | 76.005.70 | 71.883.15 | *4.93**0.0849* | 56.785.39 | 82.203.79 | 80.482.82 | *13.96**0.0009* | 57.505.77 | 81.463.89 | 77.442.65 | *9.32**0.0095* |
|  Easily Fatigued, % SE | 61.045.06 | 52.894.76 | 57.755.53 | *0.45**0.7981* | 59.435.51 | 55.625.05 | 60.154.92 | *0.34**0.8396* | 53.457.29 | 55.655.18 | 63.695.14 | *1.52**0.4671* |
|  Poor Concentration, %  SE | 83.413.57 | 80.634.05 | 87.863.74 | *1.23**0.5397* | 82.772.50 | 82.772.50 | 89.822.57 | *4.28**0.1174* | 72.698.66 | 82.702.37 | 90.902.38 | *5.94**0.0511* |
|  Irritable, % SE | 65.254.95 | 70.875.70 | 75.685.84 | *0.75**0.6877* | 67.094.97 | 72.283.38 | 77.535.16 | *1.190.5522* | 66.055.39 | 71.213.05 | 76.084.28 | *1.13**0.5677* |
|  Muscle Tension, % SE | 33.946.19 | 45.994.64 | 54.515.74 | *3.00**0.2233* | 35.324.10 | 48.964.39 | 49.633.75 | *3.41**0.1819* | 36.855.73 | 46.704.16 | 48.563.39 | *2.20**0.3332* |
|  Sleep Disturbance, %  SE | 56.197.97 | 72.564.17 | 73.075.06 | *1.76**0.4158* | 63.725.26 | 69.064.11 | 75.773.96 | *2.03**0.3629* | 69.135.47 | 69.663.74 | 73.943.51 | *0.59**0.7436* |
|  Only Restlessness or  Muscle Tension, % SE | 66.246.00 | 82.724.26 | 75.685.84 | *2.84**0.2407* | 68.204.38 | 87.242.79 | 83.912.70 | *12.47**0.0020* | 74.634.24 | 86.362.94 | 80.622.72 | *4.90**0.0864* |
| **Number of Symptoms** |  |  |  |  |  |  |  |  |  |  |  |  |
|  One Symptom, % SE | 14.985.20 | 5.141.21 | 5.724.30 | *2.11**0.3478* | 10.693.70 | 4.161.07 | 3.662.85 | *2.83**0.2434* | 8.803.01 | 3.670.94 | 3.312.42 | *2.70**0.2590* |
|  Two Symptoms, % SE | 12.142.47 | 12.764.34 | 11.773.18 | *0.03**0.9848* | 16.244.68 | 13.303.21 | 10.542.26 | *0.96**0.6186* | 12.713.80 | 15.913.40 | 13.732.15 | *0.28**0.8712* |
|  Three Symptoms, % SE | 17.183.31 | 13.533.22 | 13.302.29 | *0.10**0.9525* | 18.983.23 | 13.393.95 | 13.133.30 | *0.57**0.7523* | 29.327.99 | 13.423.65 | 11.463.21 | *4.09**0.1292* |
|  Four Symptoms, % SE | 28.199.25 | 35.047.67 | 19.003.25 | *3.31**0.1915* | 25.066.25 | 28.725.22 | 19.752.62 | *2.21**0.3318* | 23.085.39 | 26.404.95 | 19.262.41 | *1.59**0.4519* |
|  Five Symptoms, % SE | 13.463.90 | 14.624.14 | 26.523.91 | *4.87**0.0875* | 14.733.79 | 18.163.60 | 27.973.52 | *4.42**0.1097* | 15.364.07 | 18.093.37 | 25.623.65 | *2.54**0.2812* |
|  Six Symptoms, % SE | 14.057.12 | 18.913.00 | 23.693.30 | *0.92**0.6299* | 14.294.52 | 22.283.52 | 24.962.76 | *2.03**0.3629* | 10.723.89 | 22.503.67 | 26.623.36 | *5.47**0.0650* |
|  Number of Symptoms, *M* (SE) | 3.55(0.25) | 3.98(0.20) | 4.19(0.24) | *1.55**0.2242* | 3.60 (0.17) | 4.10(0.14) | 4.33 (0.19) | *3.42**0.0421* | 3.56(0.15) | 4.07 (0.13) | 4.30(0.18) | *4.83**0.0130* |
| **Course Characteristics** |  |  |  |  |  |  |  |  |  |  |  |  |
|  Age At Onset (years),  *Md* (SE) | 9.76 (0.38) | 11.83(0.42) | 12.98(0.52) | *25179.49**<0.0001* | 10.07(0.36) | 12.23(0.22) | 12.83(0.36) | *74540.23**<0.0001* | 9.58(1.02) | 12.41(0.25) | 12.74(0.26) | *114932.19**<0.0001* |
|  12-month/LT ratio, %  SE | 59.628.31 | 45.115.13 | 65.134.64 | *5.95**0.0511* | 57.976.13 | 47.605.80 | 60.054.12 | *2.57**0.2772* | 46.027.19 | 47.995.51 | 56.423.62 | *1.41**0.4931* |
|  Number of Past Year  Episodes, *M* (SE) | 2.44(0.58) | 1.95(0.24) | 2.16(0.18) | *35.31**<.0001* | 2.45(0.35) | 2.21(0.18) | 2.05(0.12) | *8.11**0.0011* | 2.53(0.31) | 2.50(0.24) | 2.02(0.11) | *16.72**<0.0001* |
|  Number of Lifetime  Episodes, *M* (SE) | 5.64(1.34) | 6.00(0.63) | 8.86(1.69) | *1.46**0.2440* | 6.37(1.26) | 5.12(0.45) | 7.79(1.38) | *2.00**0.1488* | 5.80(0.89) | 7.17(1.75) | 7.07(1.18) | *0.42**0.6569* |
|  Longest Lifetime  Episode (months), *M* (SE) | 56.00(12.98) | 41.43(8.96) | 40.03(8.30) | *0.64**0.5333* | 30.40(8.76) | 26.69(6.44) | 26.91(5.46) | *0.08**0.9264* | 34.72(9.42) | 24.91(5.85) | 26.64(4.80) | *0.40**0.6733* |
|  Time in Episode Since Onset (months), % SE | 77.596.92 | 64.595.28 | 62.695.71 | *2.06**0.1410* | 51.166.25 | 49.365.08 | 47.775.22 | *0.10**0.9046* | 57.519.53 | 49.694.81 | 44.714.48 | *0.96**0.3917* |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3mo = duration was relaxed to at least 3 months; GAD-3mo/NOU = duration was relaxed to at least 3 months and uncontrollability criterion was not applied; a reports based on parent self-administered questionnaire sample (n = 6,483).

**Supplementary Tables S4. Severity and Impairment of Threshold and Subthreshold Generalized Anxiety Disorder**

|  |  |
| --- | --- |
|  | **GAD Definition** |
|  | **GAD-6mo****n = 284** | **GAD-3mo****n = 463** | **GAD-3mo/****NOU** **n = 545** | **GAD-6mo****vs.****Unaffected** | **GAD-3mo****vs.****Unaffected** | **GAD-3mo/NOU****vs.****Unaffected** |
| **Severity and Impairment** |  |  |  |  |  |  |
|  Severe Cases, % SE | 42.04 (4.25) | 39.49 (3.60) | 35.65 (2.83) |  |  |  |
| Wald χ21 (*p*) |  |  |  | 35.24 (<0.0001) | 59.93 (<0.0001) | 57.62 (<0.0001) |
|  Past Year Impairment, *M* (SE) | 6.94 (0.21) | 6.76 (0.26) | 6.81 0.25 |  |  |  |
| Wald  *F*1 (*p*) |  |  |  | 133.31 (<0.0001) | 649.99 (<0.0001) | 358.38 (<0.0001) |
|  Days Out of Role, *M* (SE) | 7.37 (1.60) | 7.69 (1.42) | 7.55 1.49 |  |  |  |
| Wald  *F*1 (*p*) |  |  |  | 0.10 (0.7539) | 54.49 (<0.0001) | 196.68 (<0.0001) |
|  GAD Treatment Contact, % SE | 37.25 (3.37) | 31.32 (2.45) | 27.77 2.38 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 69.42 (<0.0001) | 127.08 (<0.0001) | 145.73 (<0.0001) |
|  Anxiety Treatment Contact, % SE | 26.13 (2.75) | 22.58 (2.27) | 22.01 1.95 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 4.33 (0.0375) | 6.79 (0.0092) | 6.26 (0.0124) |
|  Any Lifetime Treatment, % SE | 53.69 (3.74) | 50.69 (3.26) | 49.34 3.17 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 9.23 (0.0024) | 18.19 (<0.0001) | 18.50 (<0.0001) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3mo = duration was relaxed to at least 3 months; GAD-3mo/NOU = duration was relaxed to at least 3 months and uncontrollability criterion was not applied; regression models controlled for all significant sociodemographic predictors (sex, age, race) and other psychiatric disorders (but the disorder of interest).

**Supplementary Table S5. Associations of Anxiety Disorder Mutually Exclusive Groups With Other Mental Disorders**

|  |  |  |
| --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | **Comparisons of** **Mutually Exclusive GAD Groups** |
|  | **Weighted Proportion % SE** | **Adjusted Odds Ratio** **(95% C.I.)** |
| **Mental Disorders** | **GAD-6mo** **n = 284** | **GAD-3-5mo** **n = 179** | **GAD-3-5mo/****NOU****n = 214** | **GAD-3-5mo** **vs.****GAD-6**  | **GAD-3-5mo/****NOU** **vs.** **GAD-6** |
| Any Anxiety Disorder, % (SE) | 65.80 (4.83) | 61.95 (2.89) | 58.85 (3.13) | 0.56 (0.31-1.03) | 0.55 (0.31-0.98) |
| Wald χ21 (p) |  |  |  | 3.48 (0.0620) | 4.09 (0.0432) |
|  Specific Phobia, % (SE) | 40.71 (2.81) | 25.23 (4.05) | 24.25 (3.51) | 0.69 (0.30-1.60) | 0.61 (0.28-1.32) |
| Wald χ21 (p) |  |  |  | 0.76 (0.3839) | 1.58 (0.2086) |
|  Social Phobia, % (SE) | 20.08 (3.74) | 23.88 (3.50) | 20.22 (3.27) | 1.33 (0.60-2.94) | 1.02 (0.46-2.27) |
| Wald χ21 (*p*) |  |  |  | 0.49 0.4857 | 0.00 (0.9626) |
|  Agoraphobia, % (SE) | 10.94(2.58) | 9.17 (3.68) | 7.55 (3.13) | 1.00 (0.32-3.14) | 0.83 (0.27-2.54) |
| Wald χ21 (*p*) |  |  |  | 0.00 (0.9956) | 0.10 (0.7467) |
|  Panic Disorder, % (SE) | 10.12 (2.37) | 9.00 (2.32) | 9.41 (2.41) | 1.34 (0.44-4.07) | 1.54 (0.54-4.40) |
| Wald χ21 (*p*) |  |  |  | 0.26 (0.6094) | 0.64 (0.4242) |
|  Separation Anxiety Disorder, % (SE) | 20.95 (4.01) | 22.63 (3.68) | 22.97 (3.60) | 0.88 (0.39-1.99) | 0.99 (0.48-2.02) |
| Wald χ21 (*p*) |  |  |  | 0.10 (0.7558) | 0.00 (0.9752) |
|  PTSD, % (SE) | 20.59 (4.21) | 18.35 (4.49) | 15.89 (4.02) | 0.26 (0.08-0.84) | 0.21 (0.07-0.61) |
| Wald χ21 (*p*)  |  |  |  | 5.06 (0.0245) | 8.16 (0.0043) |
| Any Mood Disorder, % (SE) | 58.55 (4.31) | 47.15 (4.41) | 46.15 (4.40) | 1.13 (0.52-2.45) | 1.15 (0.53-2.48) |
| Wald χ21 (*p*)  |  |  |  | 0.09 (0.7618) | 0.13 (0.7213) |
|  Major Depression, % (SE) | 54.41 (4.51) | 39.04 (3.85) | 38.86 (4.26) | 0.99 (0.49-1.98) | 0.99 (0.49-2.03) |
| Wald χ21 (*p*)  |  |  |  | 0.01 (0.9718) | 0.00 (0.9866) |
|  Dysthymia, % (SE)  | 22.61 (3.76) | 9.66 (2.47) | 10.65 (3.05) | 0.23 (0.08-0.71) | 0.32 (0.14-0.78) |
| Wald χ21 (*p*) |  |  |  | 6.59 (0.0103) | 6.52 (0.0106) |
|  Bipolar Disorder, % (SE) | 7.94 (1.71) | 13.82 (3.89) | 13.95 (3.80) | 8.58 (2.56-28.84) | 9.55 (2.69-33.87) |
| Wald χ21 (*p*) |  |  |  | 12.09 (0.0005) | 12.19 (0.0005) |
| Any Behavior Disordera, % (SE) | 29.89 (3.97) | 24.76 (3.89) | 32.14 (3.95) | 0.76 (0.32-1.82) | 0.71 (0.33-1.52) |
| Wald χ21 (*p*) |  |  |  | 0.39 (0.5342) | 0.80 (0.3721) |
|  ODDa, % (SE)  | 22.88 (4.52) | 13.86 (2.95) | 15.51 (4.11) | 0.38 (0.08-1.66) | 0.43 (0.12-1.57) |
| Wald χ21 (*p*) |  |  |  | 1.65 (0.1988) | 1.64 (0.1998) |
|  Conduct Disordera, % (SE)  | 21.12 (3.68) | 20.53 (4.20) | 20.60 (2.83) | 2.04 (0.69-6.02) | 1.85 (0.67-5.16) |
| Wald χ21 (*p*)  |  |  |  | 1.66 (0.1972) | 1.39 (0.2377) |
|  ADHDa, % (SE) | 16.78 (2.88) | 12.68 (3.57) | 15.57 (2.77) | 0.39 (0.15-1.02) | 0.44 (0.20-0.94) |
| Wald χ21 (*p*) |  |  |  | 3.72 (0.0537) | 4.45 (0.0349) |
| Any Substance Use Disorder, % (SE) | 23.61 (3.83) | 22.23 (4.23) | 21.29 (4.23) | 0.35 (0.10-1.21) | 0.43 (0.13-1.40) |
| Wald χ21 (*p*) |  |  |  | 2.74 (0.0982) | 1.97 (0.1599) |
|  Alcohol Use Disorders, % (SE) | 14.58 (3.16) | 19.30 (4.18) | 15.96 (3.72) | 0.75 (0.27-2.09) | 0.53 (0.19-1.46) |
| Wald χ21 (*p*) |  |  |  | 0.30 (0.5840) | 1.51 (0.2190) |
|  Drug Use Disorders, % (SE) | 17.26 (3.02) | 19.75 (3.83) | 19.18 (4.01) | 0.48 (0.13-1.77) | 0.61 (0.16-2.28) |
| Wald χ21 (*p*) |  |  |  | 1.23 (0.2679) | 0.54 (0.4625) |

Note. GAD = generalized anxiety disorder; PTSD = posttraumatic stress disorder, ODD = oppositional defiant disorder, ADHD =

attention deficit/hyperactivity disorder; CI = confidence interval; adjusted odds ratios and 95% confidence intervals include all

significant sociodemographic predictors (sex, age, race) and other psychiatric disorders (but the disorder of interest); a reports based on

parent self-administered questionnaire sample (n = 6,483); GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration was **≥**3 months

and **<** 6 months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability criterion was not applied.